Navigation Links
Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder
Date:5/7/2008

as acetylcholine and dopamine, and are an important class of ion channels (molecular "gates" that control the flow of ions in and out of cells and regulate neuron signaling) that have been associated with a number of neurological conditions.

"We have seen therapeutic promise in targeting NNRs for more than a decade, for both pain and the cognitive deficits associated with a variety of diseases, including ADHD and Alzheimer's disease," said James Sullivan, Ph.D., divisional vice president, Neuroscience Discovery, Abbott. "We are very encouraged with the results of our ADHD work; this is a condition that demands innovative treatments, particularly to address side effect issues that have been observed with current treatments."

"The studies evaluating efficacy demonstrated that ABT-089 reduced the severity of symptoms and was generally well tolerated in adults with ADHD," said Timothy Wilens, M.D., associate professor of psychiatry, director of Substance Abuse Services in Pediatric Psychopharmacology at Massachusetts General Hospital. "Not all NNR agonists may be suitable for the treatment of ADHD. By selectively targeting specific NNR receptors, ABT-089 appears to have a favorable profile for treating the condition."

Study Background and Results

Two-hundred-twenty-one adults with ADHD enrolled in the multicenter, randomized, double-blind, placebo-controlled study, which used a 2 x 2 crossover design. Each subject received both placebo (PBO) and active treatment in random sequence. Five doses of ABT-089 were evaluated: 2 mg, 5 mg, 15 mg, or 40 mg once daily (QD), or 40 mg twice daily (BID). Each treatment period was 4 weeks, separated by a 2-week washout period. The endpoint was the Investigator-rated Conners' Adult ADHD Rating Scale (CAARS- Inv) Total Score obtained at the end of each treatment period.

Results showed ABT-089 at doses of 40mg QD and 40 mg BID were generally well tolerated, did not negatively impact heart rate or blood
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
2. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
3. Abbott Scientists Create One Molecule With Two Antibody Functions
4. Abbott Named to Science Magazines List of Top Employers in the Biotech and Pharmaceutical Industry
5. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
6. Abbott Declares 336th Consecutive Quarterly Dividend
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Abbott to Present at JP Morgan Healthcare Conference
9. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
10. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
11. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015 ImmunoCellular Therapeutics, Ltd. ... Gengos , President and Chief Executive Officer, will ... DATE:  Thursday, May 7, 2015     TIME:  11:30 ... > click the red "register/ watch presentations" ... interactive online event where investors are invited to ...
(Date:5/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4r95kr/clinical ) ... Laboratory, Molecular Diagnostics and Genomic Testing Services Market ... Version" report to their offering. ... molecular diagnostics and pharmacogenics hold the promise of ... is moving out of the national and regional ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 GEA ... last week as recipients of the INTERPHEX Exhibitor ... recognition of their Portable, Continuous, Miniature and Modular ... a small footprint, continuous processing equipment, smart control ... process API powders and inactive ingredients into bulk ...
(Date:5/4/2015)... FRANCISCO, Calif. , May 4, 2015 /PRNewswire/ ... biopharmaceutical company focused on the development and commercialization ... announced today the completion of its merger with ... In conjunction with the closing of the merger, ... a combination of new investors and all current ...
Breaking Biology Technology:ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2European Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6
... old Web site is history. The society recently redesigned their ... Wisconsin, the latter of which exhibits quirky Wisconsin facts -- ... their whiskey during Prohibition (hint: it involves a cat). ... use this technology. , ,The XML-based RSS feeds allow specific ...
... H&Q conference in San Francisco is still seeping out (even though ... Journal), the overall sentiment from the meeting seems to be one ... IPOs queued up now. The outcome of the Eyetech IPO (expected ... of this IPO will be closely monitored. The last time the ...
... - The first-prize winner in the Governor's Business Plan ... according to a recent announcement by Secretary Cory ... $105,000 the amount already raised for prizes in the ... until Jan. 31. Gov. Doyle unveiled the contest at ...
Cached Biology Technology:Wisconsin Historical Society Embraces New Web Site Technology 22003 Biotech Results 2Business Plan Bounty Increases to $105,000 2
(Date:4/27/2015)... , April 27, 2015  For more than ... trade show has been the premier worldwide event for ... 2015 is a must-attend event for any local, national, ... into the emerging commercial markets and current applications of ... innovations of this projected $48 billion industry, and how ...
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... has again vetoed the Stem Cell Research Enhancement ... stem cell research. AAAS, the world’s largest general ... Americans spanning all parties and faiths that supports ... embryonic stem cell research is an extremely promising ...
... words — talking with a therapist or friend, writing in ... brain imaging study by UCLA psychologists reveals why verbalizing our ... , Another study, with the same participants and three of ... with ancient Buddhist teachings to provide the first neural evidence ...
... Researchers studying the genetics behind why C. difficile causes disease ... do it because they are starving. That just might help ... a very difficult disease to treat. , "The genes responsible ... of nutrient deprivation. This is consistent with the ...
Cached Biology News:AAAS decries latest stem cell veto 2AAAS decries latest stem cell veto 3Putting feelings into words produces therapeutic effects in the brain 2Putting feelings into words produces therapeutic effects in the brain 3Putting feelings into words produces therapeutic effects in the brain 4Putting feelings into words produces therapeutic effects in the brain 5Understanding why C. difficile causes disease -- it's hungry 2
... Vector is specifically designed to target and ... Saccharomyces cerevisiae. Displayed proteins can be analyzed ... or putative ligands. pYD1 uses the a-agglutinin ... domains Aga1 and Aga2 to display recombinant ...
... Aph-1a (Aph-1aL,S Loop 92-115), O2F1 Affinity ... a multiprotein complex consisting of presenilin, ... proteins are necessary for full proteolytic ... cleavage of a number of integral ...
TGase3 (S-20)...
Mouse monoclonal [HYB 232-02] to Protein S ( Abpromise for all tested applications). entrezGeneID: 5627 SwissProtID: P07225...
Biology Products: